Which only makes sense until the Aug notes become due? Then what excuses will Oncolix have for possibly having a failed product and no cash?
Then do shareholders wish that Redman re restructures the notes at a PPS of .005?
Shareholders were duped plain and simple, 700+ days in a clinical trial and not a single shareholder can say with 100% certainty that 1 single patient has been dosed with a BioVectra produced Prolanta in Current clincal trials?
Not sure now if note holders can sell below .01 with the new restrictions on MMs like BMIC who can no longer hold toxic shares for note holders and sell below .01 on OTC. That may put the floor at .01.
News 
Market Data 
Discover 
